Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
'It's doing badly': Fears grow for whale stuck off Germany's coast - 2Fundamental Home Exercise center Hardware: Amplify Your Exercises
- 3People are getting their news from AI – and it’s altering their views
- 4See tonight’s solar storm unfold across the world
- 5FDA updates risk classification for voluntary shredded cheese recall
- Hyundai Is Keeping the i30 Alive While America Keeps Losing Cars Like It
- Putin critic gets six years in penal colony, vows hunger strike
- Egypt seeks to calm tourist fears over fallout of Iran war
- U.K. blocks Kanye West from entering Britain to headline now canceled festival: What led to the ban
- How Skoda Lost Its Biggest Market In Just Seven Years
- These HGTV stars made a pledge to keep their kids off smartphones. Here's how it's going.
- Find the Advantages of Positive Nurturing: Supporting Cheerful and Sound Kids
- Figure out How to Explore Your Direction to the Best Dental Embed Trained professional: A Far reaching Manual
- Eat Well, Live Well: An Extensive Manual for Smart dieting and Sustenance
